[Interferon/Controlled study in 3-year survival of patients with osteosarcoma (author's transl)].
In eight patients with osteosarcoma we conducted a controlled tolerance study with human lymphoblast interferon. Interferon was applied for 12 months and the control period after stopping interferon has lasted 12-42 months up to now. 4 out of 8 patients who received interferon did not show any adverse reaction concerning clinical and laboratory tests during the course of a 1-year application and during the follow-up period, resp. Only reversible thrombopenias and an increase in the alpha 2-globulins fraction were observed in the interferon and in the control group, resp. All of the 8 patients have up to now survived tumor-free.
D000293:Adolescent; D000328:Adult; D000469:Alkaline Phosphatase / Q000097:blood; D000510:Alpha-Globulins / Q000378:metabolism; D001859:Bone Neoplasms / Q000188:drug therapy*; D002648:Child; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007372:Interferons / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D012516:Osteosarcoma / Q000188:drug therapy*; D010976:Platelet Count; D013997:Time Factors
D000510:Alpha-Globulins; D007372:Interferons; D000469:Alkaline Phosphatase
Verträglichkeitsprüfung von humanem Lymphoblasten-Interferon. Kontrollierte Studie bei 8 Osteosarkom-Patienten mit 3-Jahres-Uberleben.